Marlborough, Mass.-based Boston Scientific released its 2017 forecast Jan. 10, 2017, Bloomberg reports. What does the year have in store for the medical device maker?
The Latest
After announcing plans to sell off four company assets, investors rallied behind Lovell, Canada-based Valeant Pharmaceuticals.
After adding 330,000 customers in 2016, Bloomfield, Conn.-based Cigna's CEO David Cordani is aiming to add 500,000 in 2017, the Hartford Courant reports.
Analysts from TheStreet believe Parsippany-Troy Hills, N.J.-based Allergan's CEO Brett Saunders hinted the company would soon shift away from early-stage pipeline acquisitions to focus instead on research and development acquisition.
The Joint Commission awarded its first ever gold seal of approval for Methodist Dallas Medical Center's pancreatric program.
After submitting a request to expand the North Carolina's Medicaid program for 2018, the Obama administration promised swift action, while Republican lawmakers plead to CMS to reject the request, The News & Observer reports.
Japan's Takeda Pharmaceutical is acquiring Cambridge, Mass.-based Ariad Pharmaceuticals for $5.2 billion to add to its oncology pipeline, Reuters reports.
Santa Clara, Calif.-based Frost & Sullivan awarded Garden City, N.Y.-based invendo medical gmbH its 2016 North American Frost & Sullivan Award for New Product Innovation.
Lumbar spinal stenosis affects 8 percent to 11 percent of people in the United States; by 2021, around 2.4 million Americans are expected to have spinal stenosis. The typical spinal stenosis sufferer is more than 50 years old and can…
Australian researchers found physicians often underestimate the harm and overestimate the benefits of common drugs, procedures and tests, according to The Age.